Suchergebnisse - "Piani Meier, Daniela"

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis von Kappos, Ludwig, De Stefano, Nicola, Freedman, Mark S, Cree, Bruce Ac, Radue, Ernst-Wilhelm, Sprenger, Till, Sormani, Maria Pia, Smith, Terence, Häring, Dieter A, Piani Meier, Daniela, Tomic, Davorka

“… 'No evidence of disease activity' (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …”
Weitere Angaben

Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS von Sormani, Maria Pia, Kappos, Ludwig, Radue, Ernst-Wilhelm, Cohen, Jeffrey, Barkhof, Frederik, Sprenger, Till, Piani Meier, Daniela, Häring, Dieter, Tomic, Davorka, De Stefano, Nicola

“… To define values of normalized brain volume (NBV) that can be categorized as low, medium, or high, according to baseline characteristics of relapsing-remitting …”
Weitere Angaben

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis von Cree, Bruce Ac, Magnusson, Baldur, Rouyrre, Nicolas, Fox, Robert J, Giovannoni, Gavin, Vermersch, Patrick, Bar-Or, Amit, Gold, Ralf, Piani Meier, Daniela, Karlsson, Göril, Tomic, Davorka, Wolf, Christian, Dahlke, Frank, Kappos, Ludwig

“… In multiple sclerosis, impact of treatment on disability progression can be confounded if treatment also reduces relapses. To distinguish siponimod's direct …”
Weitere Angaben

Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis von Cree, Bruce Ac, Cohen, Jeffrey A, Reder, Anthony T, Tomic, Davorka, Silva, Diego, Piani Meier, Daniela, Laflamme, Annik K, Ritter, Shannon, Leppert, David, Kappos, Ludwig

“… Disease-modifying therapies (DMTs) can reduce the risk of disability worsening in patients with relapsing forms of multiple sclerosis (RMS). High-efficacy DMTs …”
Weitere Angaben

045  Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis von Arnold, Douglas L, Fox, Robert J, Bar-Or, Amit, Cree, Bruce AC, Giovannoni, Gavin, Gold, Ralf, Vermersch, Pat- rick, Meier, Daniela Piani, Arnould, Sophie, Kappos, Ludwig

“… BackgroundGrey matter (GM) loss is associated with cognitive decline and physical disability in multiple sclerosis (MS). In Phase 3 EXPAND study, siponimod …”
Volltext

Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials von Hongell, Kira, Silva, Diego G., Ritter, Shannon, Meier, Daniela Piani, Soilu-Hänninen, Merja

“… Background Low serum levels of 25-hydroxyvitamin D have been associated with worse outcomes in multiple sclerosis (MS) patients treated with interferon-beta …”
Volltext

The effect of disease modifying therapies on fatigue in multiple sclerosis von Cruz Rivera, Samantha, Aiyegbusi, Olalekan Lee, Piani Meier, Daniela, Dunne, Achille, Harlow, Danielle E, Henke, Christian, Kamudoni, Paul, Calvert, Melanie J

“… •Fatigue is a symptom with a serious impact on patients’ quality of life.•Inclusion of fatigue as an RCT outcome is crucial to understand the impact of …”
Volltext

Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey von Ziemssen, Tjalf, Giovannoni, Gavin, Alvarez, Enrique, Bhan, Virender, Hersh, Carrie, Hoffmann, Olaf, Oreja-Guevara, Celia, Robles-Cedeño, Rene R, Trojano, Maria, Vermersch, Patrick, Dobay, Pamela, Khwaja, Mudeer, Stadler, Bianca, Rauser, Benedict, Hach, Thomas, Piani-Meier, Daniela, Burton, Jason

“… Background: A digital tool, Multiple Sclerosis Progression Discussion Tool (MSProDiscuss), was developed to facilitate discussions between health care …”
Volltext

A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study von Ziemssen, Tjalf, Piani-Meier, Daniela, Bennett, Bryan, Johnson, Chloe, Tinsley, Katie, Trigg, Andrew, Hach, Thomas, Dahlke, Frank, Tomic, Davorka, Tolley, Chloe, Freedman, Mark S

“… Defining the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) can be challenging and delayed. A …”
Volltext

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence von Hach, Thomas, Shakeri-Nejad, Kasra, Bigaud, Marc, Dahlke, Frank, de Micco, Massimiliano, Petricoul, Olivier, Graham, Gordon, Piani-Meier, Daniela, Turrini, Renato, Brinkmann, Volker, Nicoletti, Ferdinando

“… Maladjusted immune responses to the coronavirus disease 2019 (COVID-19), for example, cytokine release syndrome, may result in immunopathology and acute …”
Weitere Angaben

Predicting risk of secondary progression in multiple sclerosis: A nomogram von Manouchehrinia, Ali, Zhu, Feng, Piani-Meier, Daniela, Lange, Markus, Silva, Diego G, Carruthers, Robert, Glaser, Anna, Kingwell, Elaine, Tremlett, Helen, Hillert, Jan

“… We aimed at designing a nomogram, a prediction tool, to predict the individual's risk of conversion to secondary progressive multiple sclerosis (SPMS) at the …”
Weitere Angaben

141 Cognitive processing speed predicts disease progression in SPMS: post hoc analysis from the EXPAND study von Penner, Iris-Katharina, Giovannoni, Gavin, Chitnis, Tanuja, Vermesch, Patrick, Arnould, Sophie, DeLasHeras, Virginia, Karlsson, Goeril, Piani-Meier, Daniela, Kappos, Ludwig, Benedict, Ralph

“… ObjectiveAssess the predictive value of cognitive processing speed (CPS), using the Symbol Digit Modali- ties Test (SDMT) score, on disability progression in …”
Volltext

142 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment von Penner, Iris Katharina, Heras, Virginia de las, Jones, Eddie, Castro, Patricia Dominguez, Bezlyak, Vladimir, Piani-Meier, Daniela, Lines, Carol

“… IntroductionApproximately 34%-65% of people with multiple sclerosis (pwMS) develop cognitive impair- ment (CI). CI often encompasses information processing …”
Volltext

147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy von Vermesch, Patrick, Gold, Ralf, Bar-Or, Amit, Cree, Bruce, Fox, Robert, Giovannoni, Gavin, Li, Bingbing, Piani-Meier, Daniela, Karlsson, Goeril, Kappos, Ludwig

“… AimTo evaluate changes in retinal thickness (µm), including the retinal nerve fibre layer (RNFL) and combined ganglion cell and inner plexiform layers (GCIPL), …”
Volltext

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years von Cree, Bruce Ac, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph Hb, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig

“… Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic …”
Weitere Angaben

Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial von Arnold, Douglas L, Piani-Meier, Daniela, Bar-Or, Amit, Benedict, Ralph Hb, Cree, Bruce Ac, Giovannoni, Gavin, Gold, Ralf, Vermersch, Patrick, Arnould, Sophie, Dahlke, Frank, Hach, Thomas, Ritter, Shannon, Karlsson, Göril, Kappos, Ludwig, Fox, Robert J

“… Magnetic resonance imaging (MRI) measurements of gray matter (GM) atrophy and magnetization transfer ratio (MTR; correlate of myelination) may provide better …”
Weitere Angaben

Learning ability correlates with brain atrophy and disability progression in RRMS von Sormani, Maria Pia, De Stefano, Nicola, Giovannoni, Gavin, Langdon, Dawn, Piani-Meier, Daniela, Haering, Dieter A, Kappos, Ludwig, Tomic, Davorka

“… ObjectiveTo assess the prognostic value of practice effect on Paced Auditory Serial Addition Test (PASAT) in multiple sclerosis.MethodsWe compared screening …”
Volltext

A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians’ and patients’ views von Ziemssen, Tjalf, Tolley, Chloe, Bennett, Bryan, Kilgariff, Sarah, Jones, Eddie, Pike, James, Tomic, Davorka, Piani-Meier, Daniela, Lahoz, Raquel

“… •The mechanisms of transition from RRMS to SPMS are poorly understood.•This was the first stage of development of a novel tool to assess the signs of …”
Volltext

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study von Gold, Ralf, Piani-Meier, Daniela, Kappos, Ludwig, Bar-Or, Amit, Vermersch, Patrick, Giovannoni, Gavin, Fox, Robert J., Arnold, Douglas L., Benedict, Ralph H. B., Penner, Iris-Katharina, Rouyrre, Nicolas, Kilaru, Ajay, Karlsson, Göril, Ritter, Shannon, Dahlke, Frank, Hach, Thomas, Cree, Bruce A. C.

“… Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; …”
Volltext

Lost in translation: rethinking animal models of progressive MS (an industry perspective) von Von Raison, Florian, Zaratin, Paola, Stangel, Martin, Shimshek, Derya, Nuesslein-Hildesheim, Barbara, Locatelli, Giuseppe, Collin, Ludovic, Foo, Lynette, Jafari, Mehrnoosh, Peelen, Evelyn, Kohlhof, Hella, Hagan, Nellwyn, Meier, Daniela Piani, Boschert, Ursula, Salvetti, Marco

“… •Multiple sclerosis is a complex demyelinating disorder of the central nervous system.•There is a clear unmet need for therapies that treat progressive forms …”
Volltext